News

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. The placebo-controlled, double-blind, ascending single dose

IPX159 is an oral controlled-release formulation of a small molecule that has an established pharmacological and safety profile for non-RLS use outside the US. The multicenter, randomized, double-blind,

Aviir’s TruRisk technology consists of a blood test that measures the blood levels of 7 proteins associated with the development of unstable plaque. It then uses a complex

Exparel combines bupivacaine with DepoFoam, a proven product delivery technology that delivers bupivacaine for an extended period of time, providing analgesia with reduced opioid requirements for up to

The two Novato facilities are said to support up to $1bn in revenue for BioMarin’s growing enzyme replacement therapy portfolio. BioMarin CEO Jean-Jacques Bienaime said the company is

According to the company, the one-year Target Validation Funding Award will support pathway validation experiments to show the efficacy of novel biased ligands to the delta-opioid receptor in

According to both the companies commercialization of biosimilar products will not follow a pure brand or generic model. As per the collaboration, Amgen will take up developing, manufacturing

RP104 is a proprietary delayed-release tablet formulation of cysteamine bitartrate, used as a treatment option for non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD)

The results demonstrated that GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrotic cells were present. The study also suggests